Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2017 Nov 17;7:15763. doi: 10.1038/s41598-017-16119-5

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2017

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Effects of MAM of prepubertal COCs or DOs with roscovitine or H89 in the presence of db-cAMP on GVBD, chromatin configuration and developmental potential. Panel A shows percentages of GV-intact oocytes following MAM of COCs for 4 h with 50 (50/4), 25 (25/4) or 12.5 (12.5/4) µM roscovitine or for 24 h with 3 µM roscovitine (3/24). Panels B and C show percentages of oocytes with different chromatin configurations after MAM of COCs with db-cAMP and/or different concentrations of roscovitine for 4 and 24 h, respectively. Panels D and E show percentages of oocytes with different chromatin configurations and embryo development, respectively, after MAM of DOs with db-cAMP for different times. Panels F and G show percentages of oocytes with different chromatin configurations and embryo development, respectively, after MAM of COCs with roscovitine or H89 with or without db-cAMP for 12 h. FC: freshly collected oocytes; dbc: 100 µM db-cAMP alone; dR50, 25, 12.5 and 3: 100 µM db-cAMP plus 50, 25, 12.5 or 3 µM roscovitine, respectively; d+R and d+H: 100 µM db-cAMP plus 6 µM roscovitine or 5 µM H89, respectively; MII: metaphase II/cultured oocytes; Act: activated/MII oocytes; 2-C: 2-cell embryos/activated oocytes; 4-C: 4-cell/2-cell embryos; Blst: blastocyst /4-cell embryos. Each treatment was repeated 3–5 times with each replicate including about 30 oocytes. a-d: Values with a different letter above bars differ significantly (P < 0.05).